Core Viewpoint - Hisamitsu Pharmaceutical is planning a management buyout to take the company private for nearly 400 billion yen ($2.55 billion) [1] Company Summary - Hisamitsu Pharmaceutical aims to execute a management buyout, indicating a strategic shift towards privatization [1] - The buyout is valued at approximately 400 billion yen, equivalent to $2.55 billion, highlighting the significant financial commitment involved [1]

Core Viewpoint - Crinetics Pharmaceuticals, Inc. has announced a public offering of 7,620,000 shares at a price of $45.95 per share, aiming to raise approximately $350 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The offering consists entirely of shares sold by Crinetics, with a 30-day option for underwriters to purchase an additional 1,143,000 shares [1]. - The expected closing date for the offering is around January 8, 2026, pending customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for commercial activities related to the launch of PALSONIFY™, R&D of product candidates, and general corporate purposes, including capital expenditures and working capital [2]. - Crinetics may also consider using a portion of the proceeds for in-licensing, acquiring, or investing in complementary businesses or technologies, although there are no current commitments to do so [2]. Group 3: Company Overview - Crinetics Pharmaceuticals focuses on developing novel therapeutics for endocrine diseases and related tumors, with expertise in targeting G-protein coupled receptors (GPCRs) [6]. - The company's lead product, PALSONIFY™ (paltusotine), is the first oral treatment approved by the FDA for adults with acromegaly who have not responded adequately to surgery [7]. - Crinetics has a pipeline of over 10 disclosed programs, including candidates for congenital adrenal hyperplasia and neuroendocrine tumors, addressing various endocrine conditions [7].

On Tuesday, U.S. stocks experienced a positive trading session. The Dow Jones Industrial Average climbed over 480 points, marking a 0.99% increase to 49,462.08. The NASDAQ also saw gains, rising 0.65% to 23,547.17, while the S&P 500 increased by 0.62% to 6,944.82.These are the top stocks that gained the attention of retail traders and investors throughout the day.SanDisk Corporation (NASDAQ:SNDK)SanDisk shares soared by 27.56%, closing at $349.63. The stock reached an intraday high of $352 and a low of $288 ...

Core Insights - Crinetics Pharmaceuticals, Inc. is preparing to host a conference call on January 5, 2026, to discuss the commercialization of PALSONIFY, the first FDA-approved oral treatment for acromegaly, and to share results from the Phase 2 trial of atumelnant for congenital adrenal hyperplasia [1][6] Group 1: Company Overview - Crinetics focuses on developing treatments for endocrine diseases, utilizing small molecules that target G-protein coupled receptors (GPCRs) [2] - The company's pipeline includes atumelnant for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, as well as CRN09682 for SST2 expressing tumors [2] Group 2: Financial Performance - Evercore ISI has maintained an "Outperform" rating for CRNX, raising the price target from $80 to $90, despite the stock price being $52.57 and a negative price-to-earnings (P/E) ratio of -10.29 [3] - The company has a high price-to-sales ratio of 2,856.31 and an elevated enterprise value to sales ratio of 2,816.08, indicating that investors are paying a premium for its sales [4] - Crinetics has a negative earnings yield of -9.72%, but maintains a low debt-to-equity ratio of 0.046, reflecting minimal reliance on debt [5] - The company exhibits a strong liquidity position with a current ratio of 15.12, indicating it can comfortably cover its short-term liabilities [5]

Core Insights - Astellas Pharma Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference, highlighting its strategic focuses and progress in delivering long-term impact for patients, partners, and shareholders [1][2] Company Strategy and Leadership - President and CEO Naoki Okamura will discuss Astellas' key growth drivers and commitment to disciplined execution, while Chief Research & Development Officer Tadaaki Taniguchi will emphasize advancements in transformative scientific breakthroughs for diseases with high unmet medical needs [2][3] - The company aims to turn innovative science into meaningful value for patients and drive sustainable growth, using the conference as a platform to engage with the global investment and healthcare community [3] Event Details - The presentation will take place on January 12, 2026, at 3:00 p.m. PT at the Westin St. Francis, San Francisco, with materials and a live webcast available on Astellas' Investor Relations page [8] Industry Engagement - Astellas is also a distinguished sponsor of the Biotech Showcase, further enhancing its visibility in the global life sciences community, with Chief Strategy Officer Adam Pearson participating in discussions on partnering trends that advance emerging technologies and drug development innovation [4]

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its intention to offer, subject to market and other conditions, $500 million aggregate principal amount of convertible senior notes due 2032 (the "notes†) and $200 million of common stock in separate public offerings registered under the Securities Act of 1933, as amended. Arrowhead also expects to grant the underwriters of the note offering a 30-day option to purchase up to an additional $75 milli. ...

In this article, we will take a look at some of the best dividend aristocrat stocks to invest in.Dividends play a real role in equity returns. Over long stretches of time, they add up. Since 1926, dividends have made up about 31% of the S&P 500’s total return, while capital appreciation accounts for the remaining 69%. That split matters when thinking about long-term results.For most investors, total return is not just about price gains. Steady dividend income and the ability for a stock to grow over time bo ...

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. This article is intended to provide informational content and should not be viewed as an exhaustive an ...

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd." or the "Company") (NASDAQ: TLX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Telix Pharmaceuticals Ltd. investors who were adversely affected by alleged securities fraud between February 21, 2025 and August 28, 2025. Follow the link below to get more information and be contacted by a member of our team: ht ...

Bayer's Monsanto sued COVID-19 vaccine makers Pfizer , BioNTech and Moderna in Delaware federal court on Tuesday for allegedly misusing its messenger RNA technology in manufacturing their vaccines, a ... ...